Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic methods using prostaglandin EP4 agonist components

a technology of prostaglandin and components, applied in the direction of biocide, drug composition, elcosanoid active ingredients, etc., can solve the problems of bleeding, erosion, ulcers, etc., and achieve the effect of improving or maintaining the health status of the individual and being easy to practi

Inactive Publication Date: 2007-05-31
ALLERGAN INC
View PDF19 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0039] The present invention relates to methods of treating or preventing one or more diseases or conditions, for example, of the mammalian body. Treating or preventing such disease(s) or condition(s) provides one or more substantial advantages, for example, enhances or maintains the health status of the individual, for example, human or animal, afflicted with or prone to affliction with such disease(s) or condition(s). The present methods are relatively easy to practice.

Problems solved by technology

One of the unavoidable side effects of NSAIDs is the risk of injury to the mucosal layer of the gastrointestinal (G.l.) tract, which may result in bleeding, erosion and / or ulcers.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic methods using prostaglandin EP4 agonist components
  • Therapeutic methods using prostaglandin EP4 agonist components
  • Therapeutic methods using prostaglandin EP4 agonist components

Examples

Experimental program
Comparison scheme
Effect test

examples 1 to 5

[0174] A series of five (5) tablet compositions are produced using two (2) different prostaglandin EP4 agonists and three (3) different prostaglandin EP4 agonist prodrugs. Each of the tablet compositions is prepared as follows.

[0175] Within a dust containment area, a mixture of ingredients is prepared and blended until the mixture is uniform. The uniform mixture, having a composition as listed in the table directly below, is then used in a conventional tabletting machine to produce 100 mg tablets having such composition. The tablets may be packaged, for example, in high density polyethylene bottles, with appropriate silica gel packs, capped and labeled.

[0176] The mixtures and tablets have the following make-ups:

Composition12345Ingredientwt. %wt. %wt. %wt. %wt. %Prostaglandin EP410.0————Agonist 1(1)Prostaglandin EP4—10.0———Agonist Prodrug 1(2)Prostaglandin EP4——10.0——Agonist 2(3)Prostaglandin EP4———10.0—Agonist Prodrug 2(4)Prostaglandin EP4————10.0Agonist Prodrug 3(5)Sugar50.050....

examples 6 to 9

[0177] A series of four (4) capsule compositions are produced using two (2) prostaglandin EP4 agonists and two (2) prostaglandin EP4 agonist prodrugs. Each of these capsule compositions is prepared as follows.

[0178] Within a dust containment area, small sugar spheres are provided. An aqueous mixture of the agonist or prodrug including a binder / sealer, such as Opadry® clear, is provided and is sprayed onto the sugar spheres using a conventional fluid bed spraying system. A second mixture including a binder / sealer, e.g., Opadry® clear, in a liquid carrier is sprayed onto the first sprayed spheres using a conventional fluid bed spraying system. This step results in agonist or prodrug loaded pellets with a sealing coat.

[0179] These pellets are coated with an aqueous mixture of triethyl citrate, talc and a methacrylic acid copolymer using a conventional fluid bed spraying system. This step results in agonist or prodrug loaded pellets with a sealing coat and an outer enteric coating. Th...

examples 10 to 14

[0181] Five adult humans are diagnosed with esophageal ulcers. Each of these people orally takes a tablet produced as described in Examples 1 to 5 having a different one of Compositions 1 to 5 once daily for twelve weeks. At the end of this period of time, each of the humans reports substantial relief from the esophageal ulcers. The pain and / or other symptoms of the ulcers have been reduced. In addition the ulcers have been reduced in size or substantially completely healed.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

Methods are provided directed to adminstering a therapeutically effective amount of a prostaglandin EP4 agonist component to a mammal afflicted with or prone to affliction with a disease or condition selected from an esophageal ulcer, alcohol gastrophathy, a duodenal ulcer, non-steroidal anti-inflammatory drug-induced gastropathy, non-steroidal anti-inflammatory drug-induced enteropathy and intestinal ischemia. Such administration results in treating or preventing the disease or condition.

Description

RELATED APPLICATION [0001] This application is a continuation-in-part of U.S. patent application Ser. No. 11 / 291,694 filed Nov. 30, 2005, the disclosure of which is incorporated in its entirety herein by reference.FIELD OF THE INVENTION [0002] This invention relates to treating or preventing certain diseases or conditions using therapeutically active compounds. Particularly, this invention relates to methods using prostaglandin EP4 agonist components to treat or prevent certain diseases or conditions. BACKGROUND OF THE INVENTION Description of Related Art [0003] Prostaglandins can be described as derivatives of prostanoic acid which have the following structural formula: [0004] Various types of prostaglandins are known, depending on the structure and substituents carried on the alicyclic ring of the prostanoic acid skeleton. Further classification is based on the number of unsaturated bonds in the side chain indicated by numerical subscripts after the generic type of prostaglandin ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/558A61K31/557
CPCA61K9/5078A61K31/00A61K31/45A61K31/557A61K31/5575A61K31/558A61P1/00A61P1/04A61P43/00
Inventor JIANG, GUANG-LIANGIM, WHA BINWHEELER, LARRY A.
Owner ALLERGAN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com